The efficacy of dapagliflozin in patients with CKD regardless of T2DM was the subject of the DAPA-CKD trial [52], which enrolled 4304 patients with CKD and eGFR between 25 and 75 mL/min/1.73 m2 and a urine albumin-to-creatinine (UACR) ratio of 200 to 5000. This evidence concerns the gene ALB and chronic kidney disease.